Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma.

Authors

Shiva Kant, Beaumont Health
Pravin Kesarwani, Beaumont Health
Anthony R Guastella, Beaumont Health
Praveen Kumar, Beaumont Health
Stewart F Graham, Beaumont Health
Katie L Buelow, Beaumont Health
Ichiro Nakano
Prakash Chinnaiyan, Beaumont Health

Document Type

Article

Publication Date

7-1-2020

Publication Title

Molecular cancer therapeutics

Abstract

Glioblastoma is the most common primary malignant brain tumor in adults. Despite aggressive treatment, outcomes remain poor with few long-term survivors. Therefore, considerable effort is being made to identify novel therapies for this malignancy. Targeting tumor metabolism represents a promising therapeutic strategy and activation of fatty acid oxidation (FAO) has been identified as a central metabolic node contributing toward gliomagenesis. Perhexiline is a compound with a long clinical track record in angina treatment and commonly described as an FAO inhibitor. We therefore sought to determine whether this compound might be repurposed to serve as a novel therapy in glioblastoma. Perhexiline demonstrated potent

Volume

19

Issue

7

First Page

1415

Last Page

1422

Recommended Citation

Kant S, Kesarwani P, Guastella AR, Kumar P, Graham SF, Buelow KL, Nakano I, Chinnaiyan P. Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma. Mol Cancer Ther. 2020 Jul;19(7):1415-1422. doi: 10.1158/1535-7163.MCT-19-1047. Epub 2020 May 19. PMID: 32430486; PMCID: PMC7335329.

DOI

10.1158/1535-7163

ISSN

1538-8514

PubMed ID

32430486